{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:51:15Z","timestamp":1786978275629,"version":"build-2736575974"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,10,31]],"date-time":"2007-10-31T00:00:00Z","timestamp":1193788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The skeleton is the most frequently involved organ in Langerhans cell histiocytosis (LCH) in children, and bone LCH generally has an excellent long\u2010term survival. Although permanent consequences (PC) are described in half of the survivors thus raising concerns for quality of life (QOL), the impact on quality of life has not been formally studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was performed on 124 LCH patients with skeletal involvement, followed by prospective evaluation of PC and health\u2010related QOL using age\u2010appropriate validated study tools (PedsQL or SF\u201036).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 116 survivors, PC were found in 34 (29%) patients, of whom 8 had more than 1 PC. PC were significantly more frequent in multi\u2010system (M\u2010S) than in single system (S\u2010S) LCH (73% vs. 17%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). While diabetes insipidus (65%) was the most common PC in M\u2010S LCH, cosmetic and orthopedic problems made up the majority of PC in S\u2010S LCH. The median follow\u2010up time was 8.5 years. 27 patients completed the PedsQL survey and 22 the SF\u201036 survey. The QOL scores for LCH patients were not significantly different from healthy children in the PedsQL survey and from young adults in the SF\u201036 survey. In addition, the QOL scores were very similar between patients with and without PC and between patients with M\u2010S and S\u2010S LCH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Children with M\u2010S LCH had a significantly higher risk of developing PC. Skeletal LCH did not adversely affect the quality of life of survivors, including those with PC who appeared to adapt to their disabilities and medical problems. Pediatr Blood Cancer 2008;50:607\u2013612. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.21322","type":"journal-article","created":{"date-parts":[[2007,10,31]],"date-time":"2007-10-31T18:17:11Z","timestamp":1193854631000},"page":"607-612","source":"Crossref","is-referenced-by-count":43,"title":["Skeletal Langerhans cell histiocytosis in children: Permanent consequences and health\u2010related quality of life in long\u2010term survivors"],"prefix":"10.1002","volume":"50","author":[{"given":"Loretta MS","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Stuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12990-X"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1178"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230203"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950210405"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20021"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2005.tb02048.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2073"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01125.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70511-6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.048"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2"},{"key":"e_1_2_6_13_2","first-page":"265","article-title":"Canadian normative data for the SF\u201036 health survey. Canadian Multicentre Osteoporosis Study Research Group","volume":"163","author":"Hopman WM","year":"2000","journal-title":"CMAJ"},{"key":"e_1_2_6_14_2","first-page":"7","volume-title":"SF\u201036 health survey: Manual & interpretation guide","author":"Ware JE","year":"2000"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010050034300"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950080106"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70515-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.75.1.17"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199911)33:5<486::AID-MPO9>3.0.CO;2-J"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1110"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20676"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20479"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200108000-00006"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOBM.0000028500.53608.2c"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00296-X"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9280.00287"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21322","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:57:51Z","timestamp":1696867071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1002\/pbc.21322"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21322","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,9]]}}}